NextCell’s CSO elected to ISCT European Regional Secretary

March 21, 2023

NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been officially elected to the position of European Regional Secretary for the International Society for Cell and Gene Therapy.

The International Society of Cell and Gene Therapy is the global leader in pre-clinical and translational cell and gene therapeutics. Dr Davies received notification from ISCT’s President Elect, Chair of the Nominations Committee and CEO, that she had been formally elected to the role of European Regional Secretary by ISCT´s membership.

Dr Davies said, “I am delighted to receive this recognition and have the opportunity to contribute to ISCT´s next chapter and future development.”

Dr Davies will represent NextCell and Sweden for a three year term, in the European Executive Committee, a group of five elected individuals who have been selected as worldclass representatives for European CGT. “I have been an active member of the ISCT for over 10 years, with membership in the Commercialization and Process Development Committees and Particulate Working Group, representing NextCell. I am also a mentor for the ISCT´s early-stage professionals. It will be great to contribute further and give back to a Society that I have bene fitted so much from during my career.”

She continues, “I was asked by ISCT what would be at the forefront of my personal agenda for Europe´s advanced therapies forum. I replied that as an academic who transitioned to industry after many years, I would like to see greater support for academics and start-ups inside Europe to navigate the valley of death for translating their ideas to a clinical product. I would also like to make science accessible to everyone. One of the central limiting factors with cell and gene therapy development is acceptance. While we, as therapy developers, may strive to innovate and develop new medicines, if the patient doesn’t understand or is fearful of such “futuristic” therapies, there is no place for commercialization or widespread usage. Working with NextCell has shown me that irrespective of the stage of development of a new drug product, communicating science to our patients, the public, is integral to our own success.”

Dr Davies will formally commence her new role in June 2023. Further information can be read on ISCT´s webpage https://www.isctglobal.org/membership/elections

For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel:08-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
 
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
 
About NextCell Pharma AB
NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study.  ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).
 

Download attachmentRead full press release on Cision (external link)
2024-02-27
NextCell Pharma’s updated growth strategy
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.
Read moreRead more
2024-02-14
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
Read moreRead more
2024-01-25
NextCell publishes its Interim Report 1 2023/2024
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2024-01-24
Updates regarding NextCell’s Clinical Trials with ProTrans
NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.
Read moreRead more
2023-12-13
NextCell Pharma has compiled a Q&A section
NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.
Read moreRead more
2023-11-06
Repeated treatment with ProTrans is immunologically safe
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.
Read moreRead more
2023-10-26
NextCell publishes its Year-End Report 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2023-10-10
NextCell signs an agreement for a new tissue product
NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
Read moreRead more